Current research on St John's wort;Aktuelle Johanniskrautforschung

Deutsche Apotheker Zeitung

Volumn 142, Issue 10, 2002, Pages 67-95

  Wurglies, Mario ^a   Westerhoff, Kerstin ^a   Holoubek, Gisela ^a   Schubert Zsilavecz, Manfred ^a   Müller, Walter E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; HYPERIN; IMIPRAMINE; ISOQUERCITRIN; NORADRENALIN; PSEUDOHYPERICIN; QUERCETIN; RESERPINE; RUTOSIDE; SEROTONIN; SEROTONIN 2 RECEPTOR;

AGGRESSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RESEARCH; DRUG STRUCTURE; MEDICINAL PLANT; MOUSE; NEUROTRANSMISSION; NONHUMAN; STRESS;

EID: 0037034579     PISSN: 00119857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Mehr Licht in das Dunkel der Seele. Neue Antidepressiva
2. Johanniskraut. In-vitro-Studie über Hypericum Extrakt, Hypericin und Kämpferol als Antidepressiva
3. Effects of hypericum extract (Li 160) in biochemical models of antidepressant activity
4. Hyperforin as a possible antidepressant component of hypericum extract
5. The effects of extracts from St. John's wort and Kava Kava on brain neurotransmitter levels in the mouse
6. Acute and chronic actions of a dry methanolic extract of Hypericum perforatum and a hyperforin-rich extract on dopaminergic and serotoninergic neurones in rat nucleus accumbens
7. In vivo neurotransmitter release in the locus coeruleus: Effects of hyperforin, inescapable shock and fear
8. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract
9. Antidepressive Effekte von Johanniskrautextrakt und wichtigen Inhaltsstoffen im Tiermodell
10. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort
11. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity
12. Johanniskraut -Vom Nerventee zum modernen Antidepressivum
13. Pharmacological and endocrine effects of Hypericum perforatum and hypericin. After repeated treatment
14. Hyperforin-Antidepressant activity by a novel mechanism of action
15. +
16. 3H-GABA by hyperforin, a major constituent of St. John's wort: The role of amiloride sensitive sodium conductive pathways
17. Characterization of pharmacolgical activity of hyperforin in comparison with hypericum extract
18. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex
19. A study of the antidepressant activity of Hypericum perforatum on animals models
20. Hypericum extract and hyperforin: Memory-enhancing properties in rodents
21. Research in the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man
22. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test
23. Effects of Hypericum perforatum (St. John's wort) on passive avoidance in the rat: Evaluation of potential neurochemical mechanisms underlying its antidepressant activity
24. Activity profiles of two hyperforin-containing hypericum extracts in behavioral Models
25. St. John's wort, hypericin, and imipramine: A comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats
26. Plasma pharmacokinetics and cerebrospinal fluid penetration of Hypericin in nonhuman primates
27. St. John's Wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy
28. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomised, placebocontrolled, multicentre study
29. Efficacy and tolerability of Ze 117 St. John's wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10. An Overview
30. Possible relationship between behavioural and biochemical changes following antidepressant treatment
31. St. John's wort: Prozac from the plant kingdom
32. St. John's wort for depression
33. St. John's wort (Hypericum perforatum): A review of the current pharmacological, toxicological, and clinical literature
34. Hypericum perforatum - A review of clinical studies
35. The experimental and clinical pharmacology of St. John's wort (Hypericum perforatum L.)
36. Effectiveness of St. John's wort in major depression
37. The efficacy of hypericum: Does severity matter
38. Häufigkeit und klinische Relevanz der Interaktionen und Nebenwirkungen von Hypericum-Präparaten
39. Mechanismen der Interaktionen mit Johanniskrautextrakten
40. St. John's wort induces intestinal Pglycoprotein/MDR1 and intestinal and hepatic CYP3A4
41. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
42. Johanniskraut und Arzneimittelinteraktionen
43. Inhibition of Human Cytochrome P450 Enzymes by constituents of St. Johns's Wort, an herbal preparation used in the treatment of depression
44. Saint John's Wort: An in vitro analysis of Pglycoprotein induction due to extended exposure
45. Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats
46. Hyperforin affects proteolytic processing of β-amyloid precursor protein
47. Herstellung. Qualität, Analytik und Anwendung von Johanniskraut-Extrakten
48. Considerations on future pharmacopoeial monographs for plant extracts
49. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test
50. Batch-to-Batch Reproducibility of St. John's wort preparations
51. Johanniskrautextrakt-Präparate
52. Bewertung von Phytopharmaka
53. FIP guidelines for dissolution testing of solid oral products
54. Evaluation of varous dissolution media for prediciting in in vivo performance of class I and II Drugs